RECRUITING

Lung Microbiome and Inflammation in Early COPD

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a cross sectional case controlled study to assess lung microbiome and inflammation in smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will look at active bacterial metabolic pathways in the lower airways using metagenomic and metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and host immune responses in COPD and controls. Investigators believe COPD cases will have higher prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.

Official Title

Lung Microbiome and Inflammation in Early Chronic Obstructive Pulmonary Disease (COPD)

Quick Facts

Study Start:2014-05
Study Completion:2026-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02777879

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Case definition: Smokers (\>20 pack-year) with airflow obstruction (FEV1/FVC\<70) and FEV1\>50% predicted (early COPD GOLD 1 or 2)
  2. * Control definition: Smokers with normal spirometry will serve as controls.
  1. * FEV1 \< 50% NOT 70
  2. * Significant cardiovascular disease defined as abnormal EKG, known or suspected coronary artery disease or congestive heart failure.
  3. * Diabetes mellitus
  4. * Significant liver or renal disease
  5. * Severe coagulopathy (INR \> 1.4, PTT \> 40 seconds and platelet count \< 150x103 cells).
  6. * Pregnancy
  7. * ETOH use of more than \>6 beers or \>4 mixed drinks daily
  8. * Lack of capacity to provide informed consent.
  9. * Antibiotic use within the prior 2months

Contacts and Locations

Study Contact

Rosemary Schluger
CONTACT
Rosemary.Schluger@nyulangone.org

Principal Investigator

Leopoldo Segal, MD
PRINCIPAL_INVESTIGATOR
New York University Medical School

Study Locations (Sites)

New York University School of Medicine
New York, New York, 10016
United States

Collaborators and Investigators

Sponsor: NYU Langone Health

  • Leopoldo Segal, MD, PRINCIPAL_INVESTIGATOR, New York University Medical School

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-05
Study Completion Date2026-08

Study Record Updates

Study Start Date2014-05
Study Completion Date2026-08

Terms related to this study

Keywords Provided by Researchers

  • Chronic Obstructive Pulmonary Disease (COPD)

Additional Relevant MeSH Terms

  • Chronic Obstuctive Pulmonary Disease